Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Ultragenyx Pharmaceutical (RARE) over the last 3 years, with Q3 2025 value amounting to $8.0 million.

  • Ultragenyx Pharmaceutical's Treasury Shares rose 12478.2% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year increase of 12478.2%. This contributed to the annual value of $3.6 million for FY2024, which is 73171.3% up from last year.
  • As of Q3 2025, Ultragenyx Pharmaceutical's Treasury Shares stood at $173034.0, which was up 15105.41% from $173034.0 recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Treasury Shares ranged from a high of $1.7 million in Q4 2021 and a low of $7812.0 during Q1 2023
  • For the 4-year period, Ultragenyx Pharmaceutical's Treasury Shares averaged around $206884.5, with its median value being $66993.0 (2024).
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Treasury Shares soared by 83595.51% in 2024, and later soared by 12478.2% in 2025.
  • Ultragenyx Pharmaceutical's Treasury Shares (Quarter) stood at $432000.0 in 2023, then soared by 731.71% to $3.6 million in 2024, then surged by 122.4% to $8.0 million in 2025.
  • Its last three reported values are $8.0 million in Q3 2025, $8.0 million for Q2 2025, and $7.6 million during Q1 2025.